Subject index

A

acetylsalicylic acid, HPV 202–203
aconitase 22, 27
acute hypoxia
  HIF-1 5–6
  ROS 96
ADP-ribosyl cyclase 240, 242
adrenal chromaffin cells
  BK channels 142
  catecholamine release 107, 108
  cyanide 109
  innervation 115
  K^+ currents 108–109
  mitochondrial electron transport chain 109, 111
  neonatal, O_2 sensing 107, 108–112
  ROS 109–111
  rotenone 109, 114
  stress 107
AEBSF 203
AICAR 238, 245–247, 248–249, 252, 257
AMP-activated protein kinase (AMPK) 234–252
  AICAR 238, 245–247, 248–249, 252, 257
  α subunit 235
  $\alpha 1$ subunit 236, 238–239, 249
  $\alpha 2$ subunit 236
  AMP binding 235
  ATP/ADP ratio 235
  β subunit 235
  cADPR 239–240, 245–247
  carotid body 247–249
  cellular distribution 239
  γ subunit 235, 236
  HPV 238
  hypoxia 238–239
  ion channel activity 253
  metabolic stress 235, 253–254
  non-metabolic processes 235
  phenformin 238, 239, 252–253
  primary targets 235
  pulmonary selective distribution 236–238
  ryanodine-sensitive Ca^{2+} stores 239–240
  subunits 236
AMP/ATP ratio 235, 238, 254–255
AMPK kinases 235
angiogenic growth factors 4
angiopoietin 1/2 4
antimycin A 56, 58, 65, 66, 70, 160, 162, 163, 179, 180–181, 205, 209
4-AP 165, 171, 219, 223
2-APB, HPV 264–265
apocynin 203
arachidonic acid, HPV 203
ARD1, HIF1α 3
ascorbate
  FIH-1 41
  HIF hydroxylation 17
asparaginyl hydroxylase
  HIF 17, 38–39
  oxygen dependence 18–19
  see also factor inhibiting HIF-1 (FIH-1)
astrocytes
  Ca^{2+} mobilization in hypoxia 120–121, 125
  regulated control of Ca^{2+} 125
ATP 2–3
  background K^+ channels 80, 82, 85–86, 87, 89
  HPV 162–163
  ionic strength 90
ATP/ADP ratio 65–66, 235

B

bacteria, O_2 supply 133
biliverdin 143, 148

BK channels 142
CO 143, 148, 150, 154–155
HO-2 143–148
BNip3 33, 34

C

Ca^{2+} channels 119–127
astrocytes 120–121, 125
cysteine residues 172
endothelial cells 120–121, 124
HPV 184, 244, 260, 266, 270, 272–273
IP_3 120, 121, 129
mitochondria 125
ROS 122
Ca^{2+}-induced Ca^{2+} release (CICR) 256
CaM kinase 6
cancer
FIH-1 46
HIF-2 33
Krebs cycle 30–31
capacitative Ca^{2+} entry (CCE)
HPV 184, 260, 264–267, 269–270
hypoxia 122–123, 129
carbon monoxide (CO)
BK channels 143, 148, 150, 154–155
carotid body 29–30
EPO 30
haeme oxygenase 143, 148, 150, 154–155
proline hydroxylase 25–26
carotid body
AMPK 247–249
ATP/ADP ratio 65–66
BK channels 142
CO 29–30
dopamine 98
glomus (type 1) cells 54, 73
HIF-1 5–6, 8–9, 10
HO-2 55, 148, 152
hypoxia sensitivity 56–59
hypoxia sensor 36
intermittent hypoxia 36, 96–97, 98, 102
local anaesthetics 75
membrane model of chemotransduction 55
metabolism 77, 80–82
Mg^{2+} 77
mitochondria 55, 83
mitochondrial electron transport chain 56–59
mouse 275–276
O_2 sensitive K^+ channels 54–55, 75–82
paraganglioma 55, 59, 71–72
pH sensitivity 75
plasticity 97
rat and rabbit compared 69
ROS 96, 97, 98, 138
sensory long-term facilitation 96–97, 98, 103
serotonin (5-HT) 98, 100
sleep apnoea 6, 13–14, 133–134
succinate dehydrogenase 55, 59–61, 71
TASK-like potassium channels 77
temperature sensitivity 74
tissue O_2 138
zinc 77
chronic hypoxia
carotid body 5–6
compared to intermittent 34–35
HIF-1 4–6
pulmonary remodelling 4–5
ROS 96
chronic hypoxic pulmonary hypertension 162
chronic obstructive pulmonary disease (COPD)
HPV 159
pulmonary remodelling 4–5
correolide 165, 171–172
cyanide 56, 58, 65, 70, 109, 172–173, 181, 182, 209
cyclic ADP ribose (cADPR)
AMPK 239–240, 245–247
HPV 184, 185, 240, 244
NAD/NADH ratio 132
β-NADH 132, 184, 240, 242
pulmonary artery smooth muscle 240, 242–245
tissue-specific distribution 240
cyclopiazonic acid 260, 265
cytochromes, oxygen sensors 134–137

D

dantrolene, HPV 264–265
DCF 168, 180
DEC1 33
deferoxamine (DFO) 200
DETC, HPV 203
diphenylene iodonium (DPI) 164, 203
DNP 205
dopamine, intermittent hypoxia 98

E

EGLN1–3 17
endothelial cells
  Ca^{2+} mobilization in hypoxia 120–121, 124
  HIF2α 11
  HPV 159, 177, 184–185
  regulated control of Ca^{2+} 125
endothelin (ET-1) 185–186
energy state homeostasis 92
EPO 3
erythrocytes 3
erythropoietin (EPO)
  anaemia 11
  CO 30
  O_2 reduction 3

F

factor inhibiting HIF-1 (FIH-1) 39–41
  ascorbate 41
  blood vessel formation 46
  CAD repression 45
  conservation 40
  functional redundancy 44–45
  HDAC interaction 45
  HIF 17–18
  invertebrates 40
  jelly-roll catalytic core 40
  K_m for oxygen 19, 43
  low oxygen tension 27
  2-OG 41
  oxygen sensing 43–44
  peptide substrate specificity 41–42
  post-translational regulation 45
  prolyl hydroxylase interaction 20, 27–28
  quaternary structure 41
  structure 40
  therapeutic target 45–46
  tumour vascularization and growth 46
  von Hippel-Landau tumour suppressor protein (pVHL) 45
FCCP 205, 213
FRET 180, 192, 193
fumarate 22, 28
functional proteomics 142–143, 155

G

glutathione peroxidase, intermittent hypoxia 100–101

H

haeme oxygenase 1 35
haeme oxygenase 2 (HO-2)
  BKα-subunit 143–148
  carotid body 55, 148, 152
  CO 143, 148, 150, 154–155
  knockout mice 151–152
  O_2 affinity 152
  superoxide generation 155
high altitude pulmonary oedema (HAPE), HPV 160
HPH1–3 17
5-HT, intermittent hypoxia 98, 100
hydrogen peroxide
  exhaled, quantification 205–206, 211
  HPV 200–203
  redox mediator 164
  signal transduction 182
  vasoconstrictor response 194–195
hyperoxia 35
hypoxia
  definition 52
  physiologically tolerable 158
  see also acute hypoxia; chronic hypoxia; intermittent hypoxia
hypoxia-inducible factor (HIF)
  acute hypoxia 5–6
  angiopoietin 1/2 4
  ARD1 3
  ascorbate 17
  BNip3 33, 34
  CAD 16, 37–39, 45
  cancer 33
  carotid body 5–6, 8–9, 10
  chronic hypoxia 4–6
  DEC1 33
  discovery 3–4
  domain structure 16
  embryonic survival 4
  endothelin (ET-1) 185–186
  EPO 3
  feedback loop 20
  fumarate 22, 28
  HIF1α 3–4, 15, 42
  HIF1β 3, 4, 15–16
  HIF2α 11, 15, 33, 42
  HIF3α 15, 34
  hydroxylases 17–19 *see also* asparaginyl hydroxylase; prolyl hydroxylase
  hypoxia response element (HRE) 3, 15

intermittent hypoxia 6, 12, 13
iron 21–22
junD 22
lifetime 12
2-methoxyoestradiol 30
mitochondria 22, 26–27
NAD 16, 37–38
nitric oxide 29
2-OG 22
OS-9 3
oxygen-dependent proteolytic degradation 16
oxygen-insensitive regulation 50–51
PAS domain proteins 16
phosphoglycerate kinase 1 32
placental growth factor 4
platelet-derived growth factor B 4
pulmonary artery smooth muscle cells 5
pulmonary remodelling 4–5
Siah1a/2 20
succinate 22, 28
transcriptional targets 15
up and down-regulation 33
vascularization 4
VEGF 4
von Hippel-Landau tumour suppressor protein 16
hypoxia response element (HRE)
HIF 3, 15
PHD2 20
VEGF 4
hypoxic pulmonary vasoconstriction (HPV)
acetylsalicylic acid 202–203
acidosis 231–232
AEBSF 203
alkalosis 232
AMPK-α1 238
animal models 159
antimycin A 205
antioxidants 179
4-AP 165, 171, 219, 223
2-APB 264–265
apocynin 203
arachidonic acid 203
ATP 162–163
bacterial pneumonia 160
biphasic response 177, 242
8-bromo-cADPR 244, 247
Ca^{2+} channels 184, 244, 260, 266, 270, 272–273
capacitative Ca^{2+} entry (CCE) 184, 260, 264–267, 269–270
cAPDR 184, 185, 240, 244
chronic obstructive pulmonary disease 159
correolide 171–172
cyanide 182
cyclopiazonic acid 260, 265
dantrolene 264–265
deferoxamine (DFO) 200
DETC 203
disease 160
DNP 205
endothelin (ET-1) 185–186
endothelium 159, 177, 184–185
endothelium-derived factors 177, 186
fast reaction 197
FCCP 205, 213
first observation 158, 176
health 159–160
high altitude pulmonary oedema (HAPE) 160
humans 158–159
hydrogen peroxide 200–203
hyperventilation 159
ion channels 159
isolated lungs 159
K^+ channels 218–228
K_v channels 165–166, 179, 220–221, 231
KCNQ channel 225, 230
La^{3+} 260, 261, 268, 270–271
mechanisms 165–166, 177, 260
mitochondrial electron transport chain 160, 162–164, 178, 180, 197, 199, 204–205
MPP^+ 205
Na^+/Ca^{2+} exchange (NCX) 261–263
NADPH oxidase 160, 164, 178, 197, 203–204, 210
nifedipine 255
nitric oxide 202
nitroblue tetrazolium 200
Nox isoforms 164, 178
O_2 sensing 160–166, 177–179
pH 231–232
phase 1 (acute phase) 177, 184, 242, 244, 260, 265
phase 2 177, 184–186, 242, 244, 260, 265
proteases 203
protocol issues 217–218
pulmonary artery rings 159
pulmonary vascular resistance 158

redox model 160, 161, 162
reversible 197
RhoA kinase 185
ROS 166–169, 177–178, 179–182, 184–186, 196–208, 215
rotenone 205
SERCA 244–245
single-lung anaesthesia 160
store-operated channels (SOCs) 270, 273
superoxide 200–203
systemic vascular resistance 158
TASK-1 223, 232
TETA 200, 203
tiron 200
transitional circulation 159–160
verapamil 255

I

intermittent hypoxia
c-*fos* 12
CaM kinase 6
carotid body 36, 96–97, 98, 102
compared to chronic 34–35
depolarizing effects 102
dopamine 98
glutathione peroxidase 100–101
HIF-1 6, 12, 13
reoxygenation phase, free radicals 103
ROS 97, 98, 138
serotonin (5-HT) 98, 100
sleep apnoea 96
summed length 13
TH mRNA 6
IP_3 120, 121, 129
iron, HIF 21–22

J

JmjC-domain-containing proteins 41
junD 22

K

K^+ channels
adrenal chromaffin cells 108–109
ATP 80, 82, 85–86, 87, 89
carotid body 54–55, 75–82
HPV 218–228
metabolism 77, 80–82
pH 75, 223, 230, 231–232
subunits 165
K_v channels, HPV 165–166, 179, 220–221, 231
KCNQ channel 225, 230
Krebs cycle
cancer 30–31
intermediates 22, 29

L

La^{3+} 260, 261, 268, 270–271
local anaesthetic 75

M

metabolic stress 107, 235, 253–254
metabolism
modulation of background K^+ channels 77, 80–82
oxygen sensing 82–83
2-methoxyoestradiol 30
Mg^{2+} 77
mitochondria
buffers for hypoxia-induced Ca^{2+} 125
carotid body 55, 83
HIF hydroxylase 22, 26–27
MnSOD 163–164, 174
ROS 13, 115, 116–117, 122, 130
succinate 51
mitochondrial electron transport chain
adrenal chromaffin cells 109, 111
carotid body glomus cells 56–59
complex I 163, 182
complex II 182, 192, 199
complex III 163, 182, 197, 199, 205
complex IV 163, 182
HPV 160, 162–164, 178, 180, 197, 199, 204–205
mega-complexes 163
ROS 98, 163, 182–184
MnSOD 163–164, 174
mouse models 275
MPP^+ 205
multiple oxygen sensors 278
myxothiazol 56

N

Na^+/Ca^{2+} exchange (NCX), HPV 261–263
β-NAD^+ 242
NAD/NADH ratio, cADPR 132
β-NADH, cADPR 132, 184, 240, 242

NADPH oxidase
  cytosolic proteins 164, 204
  haem 154
  HPV 160, 164, 178, 197, 203–204, 210
  neuroepithelial bodies 108
  protein kinase C 204, 210, 212
  pulmonary oxygen sensor 108, 204, 211
  ROS 130, 164
  subunits 164, 204
  superoxide production 204
near infrared technology 277
neuroepithelial bodies (NEBs)
  distribution 107
  hypoxia sensing 107
  NADPH oxidase complex 108
  O_2 sensing 107–108
  perinatal 107
  vagus nerve innervation 107
nifedipine, HPV 255
nitric oxide
  HIF 29
  HPV 202
nitroblue tetrazolium 200
Nox isoforms 164, 178, 211

O

O_2
  average adult consumption 2
  respiratory system activity 3
2-OG
  FIH-1 41
  HIF 22
oligomycin 89
OS-9, HIF1α 3
oxidative phosphorylation 2

P

pancreatic β cells 65, 92
paraganglioma 55, 59, 71–72
$PGF_{2\alpha}$ 262, 266
pH, K^+ channels 75, 223, 230, 231–232
phenformin 238, 239, 252–253
phosphoglycerate kinase 1 32
physiologically tolerable hypoxia 158
placental growth factor 4
plasticware, oxygen content 52
platelet-derived growth factor B 4
prolyl hydroxylase
  CO 25–26
  expression regulation 19–20
  FIH interaction 20, 27–28
  fumarate 28
  HIF 16, 17
  hypoxia 11, 20
  hypoxia response element 20
  isoforms 17
  K_m for oxygen 18, 25
  Krebs cycle intermediates 29
  low oxygen tension 27
  oxygen dependence 18
  oxygen sensing, carotid body 9
  PHD1 17, 19–20, 28
  PHD2 17, 20
  PHD3 17, 20
  Siah1a/2 20
  succinate 30
proteases, HPV 203
protein kinase C 204, 210, 212
pulmonary artery smooth muscle cells (PASMCs)
  electrical quiescence 218–219
  energy state homeostasis 92
  HIF-1 5
  uncoupled electron flow 163
pulmonary remodelling 4–5, 13

R

reactive oxygen species (ROS) 95–99
  acute hypoxia 96
  adrenal chromaffin cells 109–111
  Ca^{2+} mobilization in hypoxia 122
  carotid body 96, 97, 98, 138
  chronic hypoxia 96
  dynamic production 131
  gene transcription 96
  HPV 166–169, 177–178, 179–182, 184–186, 196–208, 215
  hyperoxia 35
  hypoxia 13, 96, 121–122, 166–168
  inhibitory messengers 96
  intermittent hypoxia 97, 98, 138
  linear production with pO_2 132, 173–174
  measurement 205–206, 211
  mitochondria 13, 115, 116–117, 122, 130
  mitochondrial electron transport chain 98, 163, 182–184
  NADPH oxidase 130, 164
  Nox isoforms 164
  second messengers 95–96
  sleep apnoea 105

redundancy 216
RhoA kinase, HPV 185
rotenone 56, 58, 65, 66–67, 70, 71, 109, 114, 116, 160, 162, 163, 179, 205, 209

S

SDHD 55
sensory long-term facilitation 96–97, 98, 103
SERCA 244–245
serotonin (5-HT), intermittent hypoxia 98, 100
Siah1a/2 20
sleep apnoea
  arousal per night and morbidity 133–134
  carotid body 6, 13–14, 133–134
  intermittent hypoxia 96
  ROS 105
  two patterns 13
SOD2 163–164, 174
stress 107, 235, 253–254
subcellular compartmentalization 209–210
succinate (dehydrogenase)
  carotid body 55, 59–61, 71
  HIF 22, 28
  hypoxia 51
  mitochondria 51
  O_2 sensing 55, 71
  paraganglioma 55, 59, 71–72
  prolyl hydroxylase 30
superoxide 182, 194
  HO-2 155
  HPV 200–203
  NADPH oxidases 204
superoxide dismutase (SOD) mimetics 97, 101

T

TASK 77, 223, 230
TASK-1 77, 223, 230, 232
TASK-3 77, 230
TEMPO 122
thenoyltrifluoroacetone (TTFA) 56
tiron 200
triethylenetetramine (TETA) 200, 203
trolox 122
TRP proteins 260
TWIK 223

V

vascular endothelial growth factor (VEGF) 4
vascularization 4, 46
VEGF 4
verapamil 255
von Hippel-Landau tumour suppressor protein (pVHL) 16, 45

Z

zinc sensitivity 77
ZMP 239, 257
ZTP 257